Trial
NCT00003496
Antineoplaston Therapy in Treating Patients With Recurrent or Extensive-Stage Small Cell Lung Cancer
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Burzynski Research Institute
Collaborators
—
Condition
Small Cell Lung Cancer Extensive Stage
Intervention
Antineoplaston therapy (Atengenal + Astugenal)
Why stopped
slow accrual
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2017-09-28